AAPL332.35+1.01 (+0.30%) ▲|ABBV262.25-0.80 (-0.30%) ▼|ABT103.15+1.12 (+1.09%) ▲|ACN190.37-3.03 (-1.57%) ▼|ADBE250.91-6.85 (-2.66%) ▼|AMAT423.30+2.13 (+0.51%) ▲|AMD522.37+18.17 (+3.60%) ▲|AMGN376.85+1.20 (+0.32%) ▲|AMT179.31+1.60 (+0.90%) ▲|AMZN247.56-0.86 (-0.35%) ▼|AVGO342.41+3.14 (+0.92%) ▲|AXP317.11-7.32 (-2.26%) ▼|BA211.22+1.53 (+0.73%) ▲|BAC58.44-1.09 (-1.82%) ▼|BKNG173.13+1.81 (+1.06%) ▲|BLK1,047.95-10.71 (-1.01%) ▼|BMY64.15+0.42 (+0.66%) ▲|BNY155.09+0.42 (+0.27%) ▲|BRK-B520.53+3.77 (+0.73%) ▲|C135.17-1.00 (-0.73%) ▼|CAT791.36+7.82 (+1.00%) ▲|CL87.33+0.33 (+0.37%) ▲|CMCSA24.18-0.24 (-0.98%) ▼|COF206.80-0.05 (-0.02%) ▼|COP134.69-6.54 (-4.63%) ▼|COST901.54+0.19 (+0.02%) ▲|CRM250.90-4.76 (-1.86%) ▼|CSCO110.66+0.59 (+0.54%) ▲|CVS93.69-0.80 (-0.85%) ▼|CVX212.36-5.41 (-2.48%) ▼|DE674.73-9.31 (-1.36%) ▼|DHR208.10-1.27 (-0.60%) ▼|DIS107.86+1.44 (+1.35%) ▲|DUK118.65+0.88 (+0.75%) ▲|EMR148.64+1.64 (+1.12%) ▲|FDX302.91-5.35 (-1.74%) ▼|GD361.16+2.56 (+0.71%) ▲|GE317.05+10.00 (+3.26%) ▲|GEV931.29+48.48 (+5.49%) ▲|GILD148.93+2.63 (+1.79%) ▲|GM84.34-1.04 (-1.21%) ▼|GOOG342.27+0.84 (+0.25%) ▲|GOOGL345.68+0.70 (+0.20%) ▲|GS977.03+0.36 (+0.04%) ▲|HD307.77+2.29 (+0.75%) ▲|HON209.04+5.60 (+2.75%) ▲|IBM241.16-7.21 (-2.90%) ▼|INTC102.07+4.93 (+5.07%) ▲|INTU322.28-7.00 (-2.12%) ▼|ISRG386.36+9.20 (+2.44%) ▲|JNJ268.04+0.84 (+0.31%) ▲|JPM350.24-2.25 (-0.64%) ▼|KO88.43-0.28 (-0.32%) ▼|LIN465.08+2.12 (+0.46%) ▲|LLY1,144.80+8.69 (+0.76%) ▲|LMT538.64+5.18 (+0.97%) ▲|LOW196.36+1.75 (+0.90%) ▲|LRCX273.66+2.79 (+1.03%) ▲|MA570.34-2.93 (-0.51%) ▼|MCD250.76-2.02 (-0.80%) ▼|MDLZ62.60+0.50 (+0.81%) ▲|MDT94.37+0.62 (+0.66%) ▲|META677.37+7.13 (+1.06%) ▲|MMM162.64-2.03 (-1.23%) ▼|MO70.51+0.70 (+1.00%) ▲|MRK144.08+0.29 (+0.20%) ▲|MS206.86+0.58 (+0.28%) ▲|MSFT493.86-3.27 (-0.66%) ▼|MU928.86+1.26 (+0.14%) ▲|NEE81.24+0.17 (+0.20%) ▲|NFLX77.26-0.65 (-0.83%) ▼|NKE36.33+0.11 (+0.29%) ▲|NOW140.63-1.27 (-0.90%) ▼|NVDA216.18+4.01 (+1.89%) ▲|ORCL143.92+3.57 (+2.54%) ▲|PEP135.24-0.26 (-0.19%) ▼|PFE27.60+0.05 (+0.16%) ▲|PG147.89+1.22 (+0.83%) ▲|PLTR171.70-0.86 (-0.50%) ▼|PM194.01-0.11 (-0.05%) ▼|QCOM189.10+1.30 (+0.69%) ▲|RTX197.33+1.83 (+0.94%) ▲|SBUX98.02+1.44 (+1.49%) ▲|SCHW106.52-1.28 (-1.19%) ▼|SO86.57+0.62 (+0.72%) ▲|SPG205.07+0.91 (+0.45%) ▲|T26.79+0.06 (+0.21%) ▲|TMO643.94+2.55 (+0.40%) ▲|TMUS178.87-1.60 (-0.89%) ▼|TSLA361.86+5.28 (+1.48%) ▲|TXN265.97+2.54 (+0.96%) ▲|UBER70.95-0.54 (-0.76%) ▼|UNH378.37+2.43 (+0.65%) ▲|UNP283.86-0.17 (-0.06%) ▼|UPS100.67-1.71 (-1.67%) ▼|USB61.31-0.94 (-1.50%) ▼|V373.93-1.75 (-0.46%) ▼|VZ51.39-0.06 (-0.12%) ▼|WFC88.25-1.48 (-1.64%) ▼|WMT107.91-0.19 (-0.17%) ▼|XOM166.15-3.12 (-1.84%) ▼|AAPL332.35+1.01 (+0.30%) ▲|ABBV262.25-0.80 (-0.30%) ▼|ABT103.15+1.12 (+1.09%) ▲|ACN190.37-3.03 (-1.57%) ▼|ADBE250.91-6.85 (-2.66%) ▼|AMAT423.30+2.13 (+0.51%) ▲|AMD522.37+18.17 (+3.60%) ▲|AMGN376.85+1.20 (+0.32%) ▲|AMT179.31+1.60 (+0.90%) ▲|AMZN247.56-0.86 (-0.35%) ▼|AVGO342.41+3.14 (+0.92%) ▲|AXP317.11-7.32 (-2.26%) ▼|BA211.22+1.53 (+0.73%) ▲|BAC58.44-1.09 (-1.82%) ▼|BKNG173.13+1.81 (+1.06%) ▲|BLK1,047.95-10.71 (-1.01%) ▼|BMY64.15+0.42 (+0.66%) ▲|BNY155.09+0.42 (+0.27%) ▲|BRK-B520.53+3.77 (+0.73%) ▲|C135.17-1.00 (-0.73%) ▼|CAT791.36+7.82 (+1.00%) ▲|CL87.33+0.33 (+0.37%) ▲|CMCSA24.18-0.24 (-0.98%) ▼|COF206.80-0.05 (-0.02%) ▼|COP134.69-6.54 (-4.63%) ▼|COST901.54+0.19 (+0.02%) ▲|CRM250.90-4.76 (-1.86%) ▼|CSCO110.66+0.59 (+0.54%) ▲|CVS93.69-0.80 (-0.85%) ▼|CVX212.36-5.41 (-2.48%) ▼|DE674.73-9.31 (-1.36%) ▼|DHR208.10-1.27 (-0.60%) ▼|DIS107.86+1.44 (+1.35%) ▲|DUK118.65+0.88 (+0.75%) ▲|EMR148.64+1.64 (+1.12%) ▲|FDX302.91-5.35 (-1.74%) ▼|GD361.16+2.56 (+0.71%) ▲|GE317.05+10.00 (+3.26%) ▲|GEV931.29+48.48 (+5.49%) ▲|GILD148.93+2.63 (+1.79%) ▲|GM84.34-1.04 (-1.21%) ▼|GOOG342.27+0.84 (+0.25%) ▲|GOOGL345.68+0.70 (+0.20%) ▲|GS977.03+0.36 (+0.04%) ▲|HD307.77+2.29 (+0.75%) ▲|HON209.04+5.60 (+2.75%) ▲|IBM241.16-7.21 (-2.90%) ▼|INTC102.07+4.93 (+5.07%) ▲|INTU322.28-7.00 (-2.12%) ▼|ISRG386.36+9.20 (+2.44%) ▲|JNJ268.04+0.84 (+0.31%) ▲|JPM350.24-2.25 (-0.64%) ▼|KO88.43-0.28 (-0.32%) ▼|LIN465.08+2.12 (+0.46%) ▲|LLY1,144.80+8.69 (+0.76%) ▲|LMT538.64+5.18 (+0.97%) ▲|LOW196.36+1.75 (+0.90%) ▲|LRCX273.66+2.79 (+1.03%) ▲|MA570.34-2.93 (-0.51%) ▼|MCD250.76-2.02 (-0.80%) ▼|MDLZ62.60+0.50 (+0.81%) ▲|MDT94.37+0.62 (+0.66%) ▲|META677.37+7.13 (+1.06%) ▲|MMM162.64-2.03 (-1.23%) ▼|MO70.51+0.70 (+1.00%) ▲|MRK144.08+0.29 (+0.20%) ▲|MS206.86+0.58 (+0.28%) ▲|MSFT493.86-3.27 (-0.66%) ▼|MU928.86+1.26 (+0.14%) ▲|NEE81.24+0.17 (+0.20%) ▲|NFLX77.26-0.65 (-0.83%) ▼|NKE36.33+0.11 (+0.29%) ▲|NOW140.63-1.27 (-0.90%) ▼|NVDA216.18+4.01 (+1.89%) ▲|ORCL143.92+3.57 (+2.54%) ▲|PEP135.24-0.26 (-0.19%) ▼|PFE27.60+0.05 (+0.16%) ▲|PG147.89+1.22 (+0.83%) ▲|PLTR171.70-0.86 (-0.50%) ▼|PM194.01-0.11 (-0.05%) ▼|QCOM189.10+1.30 (+0.69%) ▲|RTX197.33+1.83 (+0.94%) ▲|SBUX98.02+1.44 (+1.49%) ▲|SCHW106.52-1.28 (-1.19%) ▼|SO86.57+0.62 (+0.72%) ▲|SPG205.07+0.91 (+0.45%) ▲|T26.79+0.06 (+0.21%) ▲|TMO643.94+2.55 (+0.40%) ▲|TMUS178.87-1.60 (-0.89%) ▼|TSLA361.86+5.28 (+1.48%) ▲|TXN265.97+2.54 (+0.96%) ▲|UBER70.95-0.54 (-0.76%) ▼|UNH378.37+2.43 (+0.65%) ▲|UNP283.86-0.17 (-0.06%) ▼|UPS100.67-1.71 (-1.67%) ▼|USB61.31-0.94 (-1.50%) ▼|V373.93-1.75 (-0.46%) ▼|VZ51.39-0.06 (-0.12%) ▼|WFC88.25-1.48 (-1.64%) ▼|WMT107.91-0.19 (-0.17%) ▼|XOM166.15-3.12 (-1.84%) ▼|
22.5 C
New York
Wednesday, September 16, 2026

Tag: news

newssourceFORcompanyinformationcontent1releasesmarket

Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®

REYKJAVIK, Iceland, June 08, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT16, a proposed interchangeable biosimilar to Entyvio® (vedolizumab) lyophilized vial for intravenous administration.

Share buy-back program

COMPANY ANNOUNCEMENT NO 31/2026 - June 8, 2026

Prepayments, Realkredit Danmark A/S

Company Announcement No 47/2026  

Ekstraordinære indfrielser, Realkredit Danmark A/S

Selskabsmeddelelse nummer 47/2026

PATEO Teams Up with Xunce Technology and Saimo Technology to Define a New Paradigm for In-Vehicle AI Value Exchange

SHANGHAI, June 8, 2026 /PRNewswire/ -- On June 8, PATEO (02889.HK) disclosed a voluntary announcement, announcing that it has signed a tripartite strategic cooperation framework...

Værdipapirfonden Sydinvest ajourført prospekt

(Selskabsmeddelelse 08/2026)

Decisions taken by Suominen Corporation’s Extraordinary General Meeting

Suominen Corporation’s stock exchange release on June 8, 2026, at 10:30 a.m. (EEST)

LG Teams with NVIDIA to Shape the Future with M.A.P. (Mobility / AI Infra / Physical AI)

SEOUL, South Korea, June 8, 2026 /PRNewswire/ -- LG and NVIDIA are expanding their strategic collaboration across industries, Physical AI, AI Infra and mobility...

Lumissil Introduces a High-Voltage, Dual-Channel LED Lighting Controller for 48V Automotive Systems

Flexible dual-channel LED controller for 48V automotive LDMs, supporting 5–80V multi-topology designs 
Flexible dual-channel LED controller for 48V automotive LDMs, supporting 5–80V multi-topology designs

DL Holdings’ Fourth “Victoria Harbour Night Talk”: The AI Wave: Global Investment & Hong Kong Opportunities

HONG KONG, June 8, 2026 /PRNewswire/ -- The Fourth "Victoria Harbour Night Talk" concluded successfully on June 5 at Cloud 39, The Henderson, Central,...

GoveeLife Launches Smart Countertop Ice Maker 2 Pro for Iced Coffee and Summer Hosting

The bullet ice maker delivers first ice in as fast as 3 minutes, up to 47 lb of daily ice production, and up to...

Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026

Basel, June 8th, 2026 – Novartis will present data from 10 abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026, spanning Rhapsido®  (remibrutinib) clinical trial results and real-world evidence on patient burden and treatment experience. Highlights include two late-breaking oral presentations; the Phase III RemIND trial for Rhapsido in chronic inducible urticaria (CIndU) and extension data from the Phase IIIb REMIXED trial in chronic spontaneous urticaria (CSU).

“The Rhapsido presentations at EAACI 2026 expand our understanding of BTK inhibition across multiple immune-mediated diseases and provide evidence of its potential to make a meaningful impact for patients who continue to face significant burden and limited treatment options,” said Angelika Jahreis, Global Head, Immunology Development, Novartis. “Novartis will present Rhapsido data from a long-term extension trial in chronic spontaneous urticaria, Phase III data in three types of chronic inducible urticaria, and early Phase II dose-response analysis for food allergy – together providing scientific evidence for its impact across numerous diseases.”

Abstracts accepted by EAACI include: 

onsemi Introduces Industry-First Elite Pairing Studio to Simplify Power Design

Interactive simulation tool gives engineers visibility into device level behavior and pairing trade offs, accelerating power electronics design

Solidion Technology Granted 7 New Patents on Composite Anode Materials For Batteries Targeting Humanoid Robots, Space-Based Artificial Intelligence Data Centers and the Lunar Economy

 The newly granted patents further strengthen an already globally leading portfolio of patents on anode materials for high-energy and fast-charging lithium batteriesDALLAS, June 8,...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsNews

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers